Presented by expert speakers, our webinars will give you advance insight into topics that will be covered at the event.
Can’t make the date? Still register to receive the webinar recording afterwards.
Synthetic Biology Webinar
Machine Learning for and by Synthetic Biology
Tuesday, 8 October 2019 | 09:30 AM - 10:30 AM BST
Learn more about machine learning in synthetic biology by attending our complimentary webinar hosted by Jean-Loup Faulon, Director, Institute of Systems & Synthetic Biology iSSB and Professor, University of Manchester
- Discussion on whether machine learning is needed and doable in Synthetic Biology
- Presentation of a reinforcement learning approach for optimizing cell-free composition maximizing protein production
- Exploration of neural-like computation by a metabolic perceptron to classify biomarker signals
Our free webinar is for experts interested in learning more about the latest CRISPR developments in studying disease mechanisms. This is a free event open to all, so why not register and benefit from the expertise of our speakers?
J.L. Faulon is a senior research director at the French National Institute for Agronomical Research (INRA) and also a Professor in Synthetic Biology at the University of Manchester. He is the founder and co-director of a CNRS nation-wide research network in Synthetic Biology. In the past, he has been the director of the Institute of Systems & Synthetic Biology in France (2009-2015) and a distinguished research scientist at the US DOE Sandia National Laboratories (1995-2008). For most of his career, he has been leading interdisciplinary research in synthetic biology and computational biology. He is renowned for his work on computer-aided design and in particular for the applications of retrosynthesis in synthetic biology. Originally developed in the context of metabolic engineering, the computational tools and experimental validation protocols developed by his research group are now used to engineer biosensors in whole-cell and cell-free systems for disease biomarkers detection.
Single Cell Webinar
Optimising circulating tumour cells isolation for scRNA-Seq analyses
Thursday, 10 October 2019 | 10:30 AM - 11:30 AM BST
Hosted by Guilhem Tourniaire, Scientific and Managing Director, Cellenion
Circulating tumor cells (CTCs) are shed by primary tumors into the bloodstream and thus form a key component of so-called liquid biopsies which have a significant role to play in tomorrow’s precision medicine. Their study has been shown to provide important insight into cancer screening and progression. However, to unlock their true theragnostic potential, analyzes down to single CTC level are essential. However, CTCs are very rare, and their enrichment technologies provide only a purified sample typically containing very few CTCs mixed with thousands of white blood cells. In order to successfully isolate single CTC from such scarce and low purity samples, it is essential to use a technology allowing both selection of subpopulations while preventing any loss of these few cells of interest. In this study, researchers optimized the use of Biolidics’ ClearCell FX1 system for enrichment of CTCs from blood followed by single CTC isolation with Cellenion’s cellenONE technology prior to whole transcriptome library preparation and sequencing. This study first demonstrated that combining these two systems wasn’t affecting cells as their transcriptome was largely unchanged before and after each step. Immunostaining of the white blood cell fraction in the enriched sample allowed negative selection and single CTCs isolation by cellenONE. Overall, this work demonstrated the potential of the whole process for single CTC transcriptomic analyses which will be utilized to stratify patients, to provide better personalized cancer treatments, while also allowing discovery of new relevant biomarkers.
- Why CTCs are a key component of precision medicine
- Challenges associated with single CTC isolation
- Protocol for automated single CTC isolation and their transcriptomic analyses
Guilhem Tourniaire studied Chemistry in Montpellier, after an industrial placement at Unilever in Liverpool, he decided to further his study in the United Kingdom. He graduated with a Master in Applied Chemistry from Kingston University and then undertook a doctorate in high throughput Chemical Biology under the supervision of Professor Mark Bradley at the University of Edinburgh. After graduating, Guilhem worked for several start-up companies. At Smart Holograms, he worked on the development of biosensors for glucose monitoring. At Altrika, he was project manager and developed biomaterials for stem cell culture and bacterial enrichment. In 2013, he decided to return to France and work as business developer for SCIENION AG where he established a business plan to investigate novel markets and applications related to precision cell dispensing. This latest assignment led to the creation of Cellenion in 2016, and his appointment as Scientific and Managing director of Cellenion, a SCIENION subsidiary based in Lyon, specialized in the fields of single-cell isolation and bioprinting.
Genome Editing Webinar
Generating CRISPR rodent models: challenges and solutions
Wednesday, 16 October 2019 | 02:30 PM - 03:30 PM BST
Hosted by Dr Guillaume Pavlovic – Head of Unit – Genetic Engineering and Model Validation Department PHENOMIN-ICS – IGBMC, Charles River
The use of genetically modified rodents has brought major breakthroughs in biomedical research, but a conspicuous issue remains: why do the remarkable results discovered using these in vivo models may fail to be replicated or to translate to human disease?
With new techniques such as CRISPR/Cas9-mediated genome editing, scientists now have access to a quick and low cost platform for generating a precise panel of mutations targeting a variety of backgrounds. This webinar will discuss both the incredible promise CRISPR/Cas9 has for mouse and rat studies, as well as strategies and best practice for developing accurate and predictive models to better understand the Mammalian genome and treat human diseases.
- What are in 2019 the best approaches to generate rodent models?
- Challenges with genome editing in rodent
- Best strategy to perform extensive quality control and validation of generated animal models
Dr Guillaume Pavlovic is the Head of the mouse and rat model creation core (Genetic Engineering and Model Validation Department) at Institut Clinique de la Souris (ICS) – PHENOMIN. He directs the generation and validation of genetically rodent mutants for many academic laboratories, European consortia and pharmaceutical or biotech companies (more than 2,300 models achieved to date) and animal model microbiota research.
He leads R&D programs focusing on the development of new tools for genetic engineering and microbiota analyses, and is an expert in genetics and genome editing including the CRISPR/Cas9 system.
After a PhD in 2004, about bacterial mobile elements evolution, Guillaume Pavlovic worked at genOway, one of the leader company in the generation of customized and ready-to-use genetically modified mouse and rat models to develop the molecular biology activity. He joined ICS in 2007 as project manager in charge of the mouse model projects of its main industrial customers and was appointed at his present position one year later.